Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.
about
The meningococcus and mechanisms of pathogenicityHumoral immune responses to Neisseria meningitidis in children.Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.Bexsero® chronicle.The meningococcus tamed?Meningococcal disease in ScandinaviaProtection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparationsProtection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogensMurine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparationsIntranasal immunization of mice against Pasteurella multocida.Reversible phase variation of expression of Neisseria meningitidis class 5 outer membrane proteins and their relationship to gonococcal proteins II.Effect of aluminum ions on chemical and immunological properties of meningococcal group B polysaccharideComplex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in manDevelopment of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse modelHuman opsonins to meningococci after vaccination.Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody.Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharideImmunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis.Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidisHuman immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine.Spin membrane immunoassay for use in meningococcal serologyVaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Bacterial outer membrane vesicles in disease and preventive medicine.Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978.Outer membrane antigens of Neisseria meningitidis group B serotype 2 studied by crossed immunoelectrophoresis.Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens.Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.Meningococci.Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.Status of a group B Neisseria meningitidis vaccine.
P2860
Q33626434-CD276595-77E1-4A12-86D2-5F1432926080Q33867340-D59DCBB4-969C-4104-8AC1-6C5F860786C9Q33997835-88B4740B-C3A9-4484-9652-BC9DDEB3FE2EQ34094054-721FFAF2-6826-4438-85AF-6980A17378EFQ34521773-18C9925E-F601-4A10-A8BC-A45D29E3F967Q34562726-EA8B4D6A-82F0-4E4A-889F-C3A3D67EFC4CQ34712881-15D7F19A-3A82-44E9-A879-90569F536D6CQ34760360-12856999-31D9-4FF4-BDCF-DB817206ECCCQ36329652-35832B35-25BC-43C4-A1CB-9A0D3BA6D50BQ36329679-EB92790C-777F-4CE0-95E8-59D332ADCDEEQ36445906-EF6E6D8C-E0AB-4F13-97F0-34336C43313FQ36454132-96B1F2F0-A281-4E79-A18D-0DD80209B027Q36993605-1E0A3980-91A7-49A3-8889-CD3EACEC62CAQ37032835-ADAC070F-A5AE-483B-96AD-9FDB9EF3A888Q37038027-8721A88A-2AF5-4AE3-A73C-27BD6B730AE5Q37041494-73106CCF-E2B5-4EDD-9C24-208A719C7642Q37042683-15029CBE-6B49-4934-B7A3-04727191A85AQ37049370-6674B252-13C5-417E-8173-EF6A5BC53523Q37075453-011B438F-7FAA-4058-9D0F-7330E56EA809Q37103595-D32427BF-02EB-483A-A8AE-7EE6236FF543Q37111150-0D3478DC-6410-4CAC-821E-945E665BE853Q37216248-5289D521-D798-4942-ACF3-FD9911E9902CQ37258317-FA0CC8FC-0B04-4E0C-A75A-E921252B8C1FQ37514748-75F2A118-5BE7-4812-B382-195E6F776B0EQ37820396-456E0DF4-F8F3-4AAC-8261-9896A25B3060Q39655576-8F7226B4-CA16-4651-B3B8-1108BA0F9606Q39694152-6863B0AB-CFF6-468E-A42F-BD389831FB97Q40177781-535DE09D-ED24-46DA-9806-97D676F5B265Q40182351-27944BAF-7087-43EA-B1ED-E8CE70BA6CD7Q40184215-4D24674A-AAEC-41B6-8D2F-69FF290F0F77Q40259735-4B0C3286-CA12-4F33-B75F-ADFBF797735CQ40427078-2D2922AB-E7A3-497C-AA46-38F5230BACE9Q43796650-961B91EE-E04E-4C5D-8F1B-91E304D1D585
P2860
Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年学术文章
@wuu
1978年学术文章
@zh-cn
1978年学术文章
@zh-hans
1978年学术文章
@zh-my
1978年学术文章
@zh-sg
1978年學術文章
@yue
1978年學術文章
@zh
1978年學術文章
@zh-hant
name
Safety and immunogenicity of a ...... vaccine in animals and humans.
@en
Safety and immunogenicity of a ...... vaccine in animals and humans.
@nl
type
label
Safety and immunogenicity of a ...... vaccine in animals and humans.
@en
Safety and immunogenicity of a ...... vaccine in animals and humans.
@nl
prefLabel
Safety and immunogenicity of a ...... vaccine in animals and humans.
@en
Safety and immunogenicity of a ...... vaccine in animals and humans.
@nl
P2093
P356
P1476
Safety and immunogenicity of a ...... vaccine in animals and humans.
@en
P2093
Artenstein MS
Lowenthal J
Mandrell RE
Zollinger WD
P304
P356
10.1093/INFDIS/137.6.728
P407
P577
1978-06-01T00:00:00Z